Ultimovacs ASA (OSL:ULTI) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 09, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Ultimovacs ASA Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ultimovacs ASA's float shares is 0.00 Mil. Ultimovacs ASA's total shares outstanding is 34.41 Mil. Ultimovacs ASA's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ultimovacs ASA's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ultimovacs ASA's Institutional Ownership is 5.67%.

Ultimovacs ASA Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ultimovacs ASA's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	34.41
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultimovacs ASA (OSL:ULTI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (OSL:ULTI) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

ULTIo:Sweden 7UM:Germany

Address

Ullernchausseen 64, Oslo, NOR, 0379

Website

https://www.ultimovacs.com

Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.